Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Promoting affordable access to new medicines: a State of Health in the EU webinar
9+ hour, 1+ min ago (115+ words) Access to medicines is under pressure across the EU, as rising prices for new therapies and growing demand test the limits of public budgets. Between 2020 and 2025, Member States implemented wide-ranging reforms to expand coverage, reduce out-of-pocket costs, and sustain innovation....
US push to cut drug prices could mean longer waits for European patients
12+ hour, 43+ min ago (942+ words) Last May, US President Donald Trump pushed to align drug pricing with the lowest levels among other developed nations — so-called most-favoured-nation (MFN) pricing. However, the pricing policy might have negative consequences. European patients might have to wait longer for some…...
Telix gets FDA tick as oil spoils mood
8+ hour, 30+ min ago (758+ words) The ASX steadied after last week’s beating as Telix jumped on a big FDA win and oil surged above US$107. ASX finally finds some green Telix lands a big FDA win Oil surges as Fed hike looms Just after 1pm on…...
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
14+ hour, 9+ min ago (484+ words) Definium Therapeutics to Discuss Topline Results from Phase 3 Pan The National Law Review Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK--(BUSINESS WIRE)…...
EDUCATE REVISITED: Drug safety
14+ hour, 19+ min ago (134+ words) NZDoctor Website intended for a New Zealand health professional readership EDUCATE REVISITED: Drug safety Amy van der Loo, clinical editor Over the past couple of years, we have published this informative collection of Educate articles about drug safety, including several…...
The eastward shift in the biotech world: Why India and China could lead the next wave
16+ hour, 46+ min ago (747+ words) China’s advantage is scale across discovery and development, and India in cost-efficiency and innovation footprint. For decades, the global biotechnology map was largely defined by a handful of established centres in the United States, and Europe. Boston, the Bay Area,…...
AstraZeneca's Phase 3 Trial of Combination Treatment for Breast Cancer Fails to Meet Primary Endpoint
14+ hour, 22+ min ago (48+ words) Published on 09/13/2026 at 11:24 pm EDT AstraZeneca: Share price weakness of late, should be capitalised on September 04, 2026 at 08:13 am EDT AstraZeneca Is Said to Have Explored Bristol Myers Merger Heading for a major healthcare merger between AstraZeneca and Bristol-Myers Squibb?...
AstraZeneca Stock Drops 0.43%: Full Details — JournalArta Global
15+ hour, 25+ min ago (318+ words) On September 14, 2026: price 11,708.00 GBp, trend sideways, RSI 41.1, support 11,460.00, resistance 12,476.00. technical analysis of astrazeneca stock. The momentum picture is mixed, and that is what makes this name interesting right now. The RSI at 41.1 is neutral, so the stock is neither overbought…...
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
15+ hour, 18+ min ago (124+ words) PharmaDispatch FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the…...
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
16+ hour, 1+ min ago (1584+ words) Daiichi Sankyo and AstraZeneca's Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo…...